Japan Breast Cancer Drugs Market Size & Outlook, 2023-2030
Japan breast cancer drugs, 2018-2030 (US$M)
Related Markets
Japan breast cancer drugs highlights
- The Japan breast cancer drugs generated a revenue of USD 475.6 million in 2023 and is expected to reach USD 795.4 million by 2030.
- The Japan market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2023.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Breast cancer drugs data book summary
| Market revenue in 2023 | USD 475.6 million |
| Market revenue in 2030 | USD 795.4 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
Other key industry trends
- In terms of revenue, Japan accounted for 5.5% of the global breast cancer drugs in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China breast cancer drugs is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 885.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Drugs Scope
Breast Cancer Drugs Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan breast cancer drugs outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.23% in 2023. Horizon Databook has segmented the Japan breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Rising incidence of breast cancer among Japanese women is anticipated to boost the market growth. According to Roswell Park Comprehensive Cancer Centre, in 2017, 1 out of every 38 women is estimated to be diagnosed with breast cancer in Japan. High adoption of western lifestyle and diet among youth contribute to the high incidence of the disease in Japan.
Favorable reimbursement policies have led to an increase in adoption of chemotherapy. Increased awareness and high demand for better products are among factors boosting the market in this region. Various organizations are striving to raise awareness about the disease in the country.
For instance, Japan Comprehensive Cancer Network, Breast (JCCNB) aims at promoting awareness about breast cancer treatment and provides information & support to healthcare practitioners and patients, to help them improve and maximize the quality of life.
Reasons to subscribe to Japan breast cancer drugs databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan breast cancer drugs databook
-
Our clientele includes a mix of breast cancer drugs companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into Japan breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan breast cancer drugs market size, by therapy, 2018-2030 (US$M)
Japan Breast Cancer Drugs Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
